Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: J.P who wrote (752)	3/13/1998 7:44:00 AM
From: Mark Bartlett	Respond to of 14101

J.P., I am not sure that I agree with your premise. First - they have had long periods with no news - certainly have not had a "PR every week - or month" , not by a long shot ... more news recently, that is true. In fact, in the early days, one of the major criticisms of this company by the shareholders, was they were not promoting themselves enough. The only thing that will move this stock significantly, is the approval of one of their 2 drugs. Pennsaid, the arthritis drug, is IMHO likely to be approved within the next few months (6 at the outside) - at least in Canada. They passed a significant hurdle with the FDA recently - that's positive. The reality ... drug approvals take a long time ... one must be patient. And of course, nothing is guaranteed - but as of now, things look good for this junior biotech company. MB

To: J.P who wrote (752)	3/13/1998 8:33:00 AM
From: READE SMITH	Read Replies (1) \| Respond to of 14101

I agree with Mark -- if you look at our share price using a 120- 160 day moving average -- you can see that we should be between $3.50 and $4.00. That's a good climb from $1, just over two years ago. It has not been slow and steady because -- it's a pharmaceutical -- we have big momentum players -- our TSE listing was hyped to the hilt by major brokerages (everyone was told that Pennsaid approval would occur last year -- it didn't and those with no patience or vision dropped out)-- finally -- when we move up everyone hopes that this will be the" big one" and does not want to be left out-- so they "buy high". The future will be even more volatile -- on the upside -- but the risk is diminishing.

To: J.P who wrote (752)	3/13/1998 10:20:00 PM
From: murray	Read Replies (1) \| Respond to of 14101

In response to your questions. There are probably two reasons I can think of for its price under 4.00. 1) the good news you hear are only increments towards the final approval of pennsaid, which will cause a significant breakout in price.But the real clincher are the multiple press releases with respect to W10F with its efficacy and low toxicity.It has been shown to be a very effective immune modulator,not only for AIDS, but perhaps a number immune-related diseases--ranging from cancer to lupus. THis could eventually make this company worth $80-100, comparing it to the price level of Biochem and its success with 3TC. 2) The biotech sector has been out of favor for awhile as investors have been chasing other sectors such as banks. When they have fully valued, they will come back to the biotech sector. We may even see a greater bull than the bull of 91-92. Companies are much more mature, many bios are getting final approval and ready to market their long awaited product. Then prices will surge. Hope these long-winded answers help. Cheers!!